% | $
Quotes you view appear here for quick access.

Endocyte, Inc. (ECYT) Message Board

  • immunocell immunocell Jul 27, 2012 12:19 PM Flag

    vintafolide will be one of the four major regulatory filings from Merck

    Merck continued to advance plans for four additional major regulatory filings by end of 2013 including: BRIDION (sugammadex), a neuromuscular blocker reversal agent; V503, a nine-valent vaccine for HPV; TREDAPTIVE (extended-release niacin/laropiprant), a novel candidate for multiple lipid parameters; and vintafolide, a small molecule drug conjugate for ovarian and other cancers (European Union filing);

6.36+0.01(+0.16%)3:59 PMEDT